Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Applied Materials AMAT Q1 2026 Earnings Transcript

View original at nasdaq.com
Applied Materials AMAT Q1 2026 Earnings Transcript Image source: The Motley Fool. Date Thursday, February 12, 2026 at 4:30 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Services mix continues to shift toward performance-based contracts

    80% confidence
  • Applied Materials returned capital to shareholders through repurchases and dividends, and continues to invest in R&D and capacity to support long-term growth

    80% confidence
  • Foundry-logic remains healthy with strength at leading nodes, while memory is improving, led by DRAM and HBM-related investments

    80% confidence
  • Near term, OpEx will grow modestly, below the pace of revenue, to drive operating leverage while prioritizing R&D and customer support

    80% confidence
  • R&D priorities include gate-all-around, backside power, advanced packaging, EUV adjacencies, new materials for scaling, and expanding metrology/inspection capabilities with AI-driven analytics

    80% confidence
  • Customers continue to accelerate node migrations and new 3D scaling approaches, expanding opportunity for differentiated materials engineering portfolio

    80% confidence
  • Company continues to expand capacity in critical product lines and investing in supply resiliency, with lead times improving

    80% confidence
  • Services growth is supported by expanding installed base, higher attachment to performance-based agreements, and analytics-driven optimization

    80% confidence
  • Company is investing in automation and remote capabilities to enhance uptime and yield for customers

    80% confidence
  • Company expects to continue repurchasing shares at a steady pace while funding strategic investments

    80% confidence
  • Advanced packaging is a strong growth vector driven by heterogeneous integration and AI

    80% confidence
  • Services margins are stable to improving, supported by higher attachment, software content, and productivity initiatives

    80% confidence
  • Metrology and inspection are growing as process complexity increases, with e-beam and optical platforms gaining traction

    80% confidence
  • Applied Materials delivered solid results in Q1 2026, driven by strong demand across AI, foundry-logic, and memory

    80% confidence
  • Applied Materials is well positioned for gate-all-around and backside power transitions with broad suite of solutions

    80% confidence
  • Company has seen some timing shifts typical for the industry, but no material cancellations; overall demand signals remain constructive

    80% confidence
  • Company has made progress diversifying suppliers, increasing dual-sourcing, and localizing critical components

    80% confidence
  • Company continues to comply with all regulations; demand in China remains mixed by segment, with mature nodes steady and certain leading-edge areas impacted by restrictions

    80% confidence
  • Regionally, continued momentum in the U.S. and Taiwan, with activity picking up in Korea

    80% confidence
  • EUV scaling increases requirements for patterning adjacencies, hard mask engineering, clean, and metrology/inspection

    80% confidence
  • OpEx will grow at a measured pace focused on R&D and customer enablement, with discipline on overhead

    80% confidence
  • Supply chain actions improve resiliency, reduce lead times, and support compliance with evolving trade regulations

    80% confidence
  • Visibility for HBM-related tools extends through multiple quarters given customers' capacity plans

    80% confidence
  • Both DRAM and NAND segments expected to grow through the year, with DRAM outpacing NAND near term

    80% confidence
  • Capital allocation priorities remain: invest in business for long-term growth, maintain strong balance sheet, and return excess cash through buybacks and dividends

    80% confidence
  • AI demand remains robust and broad-based, supporting sustained WFE strength with continued investment in leading-edge foundry-logic and advanced packaging

    80% confidence
  • Pipeline and customer engagements give confidence in demand durability over the coming quarters

    80% confidence
  • Gate-all-around and backside power introduce new materials and integration challenges where company's leadership in materials engineering is a key differentiator

    80% confidence
  • Pricing remains rational, reflecting the value of performance and total cost of ownership; competitive dynamics are stable

    80% confidence
  • Applied Materials differentiates with a comprehensive toolset across wafer-level packaging, hybrid bonding, and inspection/metrology

    80% confidence

Data points we hold from this source

Applied Materials, Inc. · book to bill ratio1.0 ratio
Applied Materials, Inc. · backlogelevated qualitative
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com
Applied Materials AMAT Q1 2026 Earnings Transcript — Source | Via News | Via News